Topical Dorzolamide for the Treatment of Cytoid Macular Edema in Patient With Retiniti Pigmentoa Original Reearch Article

Purpoe To determine if topical dorzolamide, a oberved with the ue of ytemic acetazolamide and methazolamide, would be effective in treating cytoid macular edema (CME) in patient with retiniti pigmentoa (RP). Deign Propective, nonrandomized clinical trial. Method etting: Intitutional. patient: Fifteen patient with CME and RP. intervention: A baeline viual acuity and optical coherence tomography (OCT) meaurement were obtained in all patient. Each one of them wa then treated with topical dorzolamide, three time a day, for at leat four week in both eye. main outcome meaure: ignificant decreae in “foveal thickne” (more than 16%) and “foveal zone thickne” (more than 11%), a meaured by OCT. Reult Thirteen (87%) of 15 patient howed a ignificant decreae in retinal thickne in at leat one eye after ue of topical dorzolamide for at leat four week. Five patient (33%) demontrated improvement in both eye. All patient, except one, who reponded howed the effect within four week, but were monitored for a period of two to nine month (average 4.5 month). Four patient (31%) who howed an initial improvement in macular edema howed worening with continued treatment. Concluion The preent tudy document the potential efficacy of topical dorzolamide for treating CME in patient with RP. We oberved that ome patient may how a “rebound phenomenon” with continued ue of the medication; hence, there i a need for careful follow-up in patient being treated.